Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024
05 Februar 2024 - 1:00PM
Business Wire
Enables the Simultaneous Measurement of 64
Molecular Interactions
At the SLAS2024 International Conference and Exhibition, Bruker
Corporation (Nasdaq: BRKR) today introduced the ground-breaking,
new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR)
instrument. The SPR #64 system has been engineered from the bottom
up to accelerate drug discovery with increased SPR throughput,
leading sensitivity and data quality. In modern drug discovery, SPR
is indispensable for the real-time, label-free biophysical
characterization of molecular interactions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240205314598/en/
‘Triceratops’ SPR #64: the all new,
high-throughput multiplexing Surface Plasmon Resonance (SPR) system
(Photo: Business Wire)
The ‘Triceratops’ SPR #64 system combines highest sensitivity
detection with a novel microfluidics concept, which via the
perpendicular rotation of the 8-channel flow cell, now facilitates
the simultaneous reading of 64 sensor spots. This ingenious design
extends SPR capabilities beyond previous limits, accelerating
screening, kinetics, epitope characterization, condition scouting,
concentration analysis, and thermodynamics. With the ‘Triceratops’
SPR #64, Bruker is now offering drug discovery customers the
highest throughput in the industry with uncompromising data
quality.
Immediate SPR #64 access and visual controls are facilitated
through a built-in touchscreen. Automation features, including
integration of any external robot, as well as the direct control
via its API, mark a new milestone in convenient SPR-based biopharma
research. The SPR #64 software integrates high performance,
flexibility, and ease of use throughout every stage, from
acquisition to final reports. Each module is intuitively designed,
offering guidance for key applications such as SPR affinity and
kinetics determination, thermodynamics, and epitope
characterization.
David Myszka, Ph.D., Director at Biosensor Tools LLC in Salt
Lake City, Utah, commented: “I was thrilled to collaborate with
Bruker’s engineers on the design of the new SPR #64 instrument. The
‘Triceratops’ system offers an awesome combination of flexibility,
sensitivity, and throughput. The days of tediously testing coupling
chemistries and surface density are long gone. With 8 independent
channels, we can test a range of conditions at the same time to
find the optimum condition in one run. Imagine how content
Goldilocks would be getting data from a single experiment ‘that was
just right’!"
Dr. Martin Kleinschmidt, Group Leader Bioanalytics in the
Department of Drug Design and Target Validation at the Fraunhofer
Institute for Cell Therapy and Immunology in Leipzig, Germany,
said: “In collaboration with Bruker, I have tested their new SPR
#64 instrument. We successfully measured over 1000
antibody-containing samples against eight different targets,
achieving consistent data in less time than with previous SPR
measurements. The new ‘Triceratops’ SPR #64 system offers a very
useful increase in throughput."
Dr. Meike Hamester, VP Label-Free Biopharma Technologies at
Bruker Daltonics, concluded: “The ‘Triceratops’ SPR #64, our
exciting new high-end SPR system for drug discovery, is nicely
complemented by Bruker’s SPR-24 Pro and SPR-32 Pro systems to meet
any throughput requirement.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240205314598/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 313-5800 E: Investor.Relations@bruker.com
Media Contact: Petra Scheffer Marketing Communications
Bruker Daltonics T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024